Overview

Comparative Study of the Effects of Telmisartan and Nebivolol

Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
0
Participant gender:
All
Summary
Τhe effectiveness of newer angiotensin-II receptor blockers and cardioselective beta-adrenergic blockers in treatment of arterial hypertension and in improvement of arterial stiffness has been established in previous studies among the hypertensive population. The present study is a comparison of the performance of two drugs, telmisartan and nebivolol, in 24h ambulatory blood pressure values and in the degree of arterial stiffness of patients with stage I arterial hypertension. Measurements will be carried out with the use of 24-h ambulatory blood pressure measurement devices and the method of pulse-wave velocity analysis. The effects of telmisartan and nebivolol are going to be compared for a total time period of 12 months. The aim of this project is to determine whether the expected decrease in arterial stiffness of subjects with stage I arterial hypertension can be attributed to the blood pressure fall solely, or to other factors as well. These factors are possibly dependent on the action of these drugs on the renin-angiotensin II-aldosterone system (RAAS) or on peripheral vasodilatory actions. The present study is going to be the first comparative test of the anti-hypertensive effects of the two pharmaceutical substances in 12 months' time, and of the elimination of total cardiovascular risk in terms of primary prevention of cardiovascular attacks.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Treatments:
Hydrochlorothiazide
Nebivolol
Telmisartan
Criteria
Inclusion Criteria: The final selection of the sample of 80 patients diagnosed with stage I
arterial hypertension will be based on the ABPM results (24h SBP/DBP ≥ 130/80 mm Hg).

Exclusion Criteria:

Patients who present with normal ABPM values at the end of the 3-month period will be
excluded from the study. Subjects diagnosed with white-coat hypertension [increased office
BP values (SBP/DBP ≥ 140/90 mm Hg) combined with normal ABPM values (24h SBP/DBP < 130/80
mm Hg)] will also be excluded from the study.

All subjects with contra-indications for submission of drugs used in the research protocol
are going to be excluded from the study. The following categories of patients will not
participate in the research: renal failure, hepatic failure, renal artery stenosis,
bronchial asthma, vasoconstrictive (Prinzmetal's) angina, hypertrophic cardiomyopathy,
aortic valve stenosis, mitral valve stenosis, sinus tachycardia, sinus bradycardia, sick
sinus syndrome, Wolff-Parkinson-White syndrome, chronic atrial fibrillation, second and
third degree atrioventricular block, right heart failure due to pulmonary hypertension,
pheochromocytoma, peripheral artery disease. Pregnant and nursing women will be excluded
from the study (history and pregnancy test).